PTH (Parathyroid Hormone) Dosing & Reconstitution Guide

Research indicates that PTH is typically administered via subcutaneous injection, with a recommended dosing frequency of once daily. The established dose range for experimental use spans from 50 to 100 mcg. This dosing range is derived from various studies examining the effects of PTH on bone density and metabolic regulation. It is crucial to consider individual experimental designs and objectives when determining the exact dosage within this range, as variations in response may occur due to factors such as the model organism or specific research endpoints. Researchers are encouraged to account for these variables to optimize their experimental outcomes.

The safety profile of PTH includes several common adverse effects, occurring in at least 5% of subjects, such as hypocalcemia, hypercalcemia, headache, paresthesia, nausea, diarrhea, vomiting, arthralgia, and hypoesthesia. Notably, a black box warning exists regarding the potential risk of osteosarcoma in rats subjected to prolonged exposure to PTH, raising questions about the clinical relevance of these findings in humans. Consequently, its use is restricted to patients whose conditions cannot be adequately managed with calcium and vitamin D alone, and it is available exclusively through the Natpara REMS program, which mandates prescriber certification, patient enrollment, and pharmacy certification. Contraindications include individuals with a heightened risk of osteosarcoma, hypersensitivity to PTH(1-84) or its excipients, and those who can achieve sufficient control through conventional supplementation.